Vizirgianakis Stavros G. Form 3 Xtant Medical / Stavros G. Vizirgianakis ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Vizirgianakis Stavros G.

(Last) (First) (Middle)

664 CRUISER LANE

(Street)

BELGRADE MT 59714

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/25/2022

3. Issuer Name and Ticker or Trading Symbol
Xtant Medical Holdings, Inc. [ XTNT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, $0.000001 par value	3,515,079(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrant	08/25/2022	08/25/2027	Common Stock	878,770(2)	0.48	D

Explanation of Responses:

1. Consists of 3,515,079 shares issued in connection with the first closing of the private placement (the "Private Placement") pursuant to the securities purchase agreement by and among Xtant Medical Holdings, Inc. and several accredited investors. Does not include 2,264,861 shares to be issued in connection with the second closing of the Private Placement, which will be issued subject to the satisfaction of certain closing conditions.

2. Consists of a warrant to purchase 878,770 shares in connection with the first closing of the Private Placement. Does not include a warrant to purchase 566,214 shares to be issued in connection with the second closing of the Private Placement, which will be issued subject to the satisfaction of certain closing conditions.

	/s/ Amy Culbert, attorney-in-fact	08/26/2022
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.